The marine alkaloid ascididemin (ASC) was shown to exert cytotoxicity even against multidrug-resistant cancer cells. Here, we address the signaling pathways utilized by ASC to trigger apoptosis in Jurkat leukemia T cells. We show that ASC (0.5-20 lM) induces a mitochondrial pathway that requires the activation of the initiator caspase-2 upstream of mitochondria. ASC-triggered apoptosis occurred independent of CD95, but required mitochondrial dysfunction. The activation of caspase-2 was shown to precede the processing of caspase-8, -9 and -3. The specific caspase-2 inhibitor zVDVADfmk abrogated ASC-induced DNA fragmentation almost completely. Overexpression of Bcl-x L blocked caspase-8 but not caspase-2 processing. Conversely, caspase-2 inhibition strongly reduced caspase-9 activation. As a possible link between caspase-2 and mitochondrial dysfunction, Bid was found to be cleaved by ASC. In addition, JNK was activated by ASC upstream of mitochondria via reactive oxygen species. The specific JNK inhibitor SP600125 partially inhibited caspase-2 and -9 processing as well as cytochrome c release and DNA fragmentation indicating that JNK contributes to, but is not necessary for ASCmediated apoptosis. Thus, ASC triggers a pathway in which early activation of caspase-2 provides a possible link between its DNA-damaging activity and the induction of mitochondrial dysfunction. The activation of JNK contributes to this signaling upstream of mitochondria.
Introduction
Ascididemin (ASC) is a pentacyclic aromatic marine alkaloid isolated form the ascidians Didemnum sp. (Kobayashi et al., 1988) and Cystodytes dellechiajei (Bonnard et al., 1995) . The alkaloid was shown to exert remarkable in vitro cytotoxicity against human colon and breast cancer as well as leukemia cell lines (Bonnard et al., 1995; Lindsay et al., 1995) . Interestingly, the compound was found to be almost equally toxic to drugsensitive and multidrug-resistant cell lines (Bonnard et al., 1995) . ASC is thus considered a promising cytotoxic agent, possibly serving as a lead in the search of treatments against chemoresistant tumor cells ( Dassonneville et al., 2000) . Although several studies have addressed the question of the molecular mechanism utilized by ASC to trigger cell death, this issue is yet largely elusive. Evidence is provided that ASC, similar to other planar pyridoacridine derivatives, is able to intercalate into DNA (Bonnard et al., 1995) . More recently, ASC was shown to inhibit purified topoisomerase II in vitro. However, experiments with cell lines sensitive or resistant to known topoisomerase I/II poisons indicated that neither topoisomerase I nor topoisomerase II is a potential cellular target for ASC (Dassonneville et al., 2000) . ASC, however, may cleave DNA by reactive oxygen species (ROS) generation due to iminoquinone reduction (Matsumoto et al., 2003) .
Cancer treatment by chemotherapy kills target cells primarily by induction of apoptosis (Kaufmann and Earnshaw, 2000) . A current view of chemotherapyinduced apoptosis suggests that cellular stress, such as DNA damage, induced by cytotoxic drugs is sensed by cellular organelles that signal the cell to undergo apoptosis (Bratton and Cohen, 2001; Ferri and Kroemer, 2001 ). Central figures in this setting are the mitochondria since most stress-induced signals seem to be finally routed via these organelles (Bratton and Cohen, 2001; Ferri and Kroemer, 2001) . The 'activation' of mitochondria is characterized by the release of cytochrome c from the mitochondrial intermembrane space into the cytosol. The released cytochrome c initiates assembly of Apaf-1 and procaspase-9 into a holoenzyme complex called 'apoptosome', which in turn processes and thus activates the initiator caspase-9 (Herr and Debatin, 2001 ). Initially processed caspase-9 activates downstream effector caspases, such as caspase-3 that cleave specific cellular substrates and thus lead to the biochemical and morphological changes of apoptosis (Herr and Debatin, 2001) . Little, however, is known about the stress-induced signaling pathways upstream of mitochondria.
Since ASC was shown to be effective even against chemoresistant tumor cells in vitro (Bonnard et al., 1995) , the aim of the present study was to gain an insight into the molecular pathways utilized by this marine alkaloid to trigger cell death. An understanding of these pathways may help to find new strategies to overcome chemoresistance.
Results

ASC induces apoptosis in Jurkat T cells independent of the CD95 death receptor
Leukemia Jurkat T cells were treated with ASC at concentrations verified to be cytotoxic (IC 50 value obtained from the MTT assay: 0.6 mM). Treated cells showed all signs of apoptosis, including cell shrinkage, membrane blebbing, chromatin condensation and fragmented nuclei visualized by HOECHST 33342-staining (data not shown). ASC-triggered apoptosis was concentration-and time-dependent. The amount of apoptotic cells was significantly increased in response to 0.5 mM ASC and increased further up to 20 mM ( Figure 1a ). The first significant DNA fragmentation was observed 8 h after ASC (5 mM) treatment (Figure 1b) .
Several DNA-damaging agents were reported to induce CD95-L expression (Beck et al., 2001) . We therefore examined whether protein synthesis is required for cell death induction. Preincubation of Jurkat cells with cycloheximide (1 mg/ml, 1 h) had no influence on ASC-mediated cell death (data not shown), indicating that protein synthesis is not a prerequisite for ASCinduced apoptosis.
To further exclude a potential signaling of ASC via the CD95 death receptor, we blocked CD95 with the neutralizing anti-CD95 antibody ZB4. Jurkat cells preincubated with ZB4 (1 mg/ml) showed a significantly reduced apoptosis in response to soluble CD95-L (100 ng/ml) compared to cells treated with CD95-L only. In contrast, ZB4 was unable to reduce ASC (5 mM)-triggered apoptosis (Figure 1c ). In fact, apoptosis was significantly increased in ZB4-and ASC-treated cells compared to cells treated with ASC only. This was most likely due to some cytotoxic potential of ZB4 itself observed in our cell system (Figure 1c ).
ASC induces mitochondrial dysfunction, which is required for apoptosis
Since the CD95 death receptor seemed not to be required, we focused on the question as to whether hallmarks of mitochondrial-mediated cell death, that is, cytochrome c release from mitochondria into the cytosol and dissipation of the electrochemical gradient (Dc m ), appear in response to ASC. We found that ASC (5 mM) induces outer (cytochrome c release) and inner (loss of Dc m ) mitochondrial membrane permeabilization (MMP). The release of cytochrome c (Figure 2a ) kinetically paralleled a decrease of mitochondrial membrane potential (Figure 2b) . Loss of Dc m and cytosolic cytochrome c was observable as early as 4 h.
Next, we investigated whether the observed dysfunction of mitochondria is required to induce ASCtriggered cell death in Jurkat T cells. We therefore treated cells overexpressing mitochondria-protecting Bcl-2 or Bcl-x L (Figure 2c , upper panel), with ASC (5 mM). Both Jurkat/bcl-x L and Jurkat/bcl-2 cells were protected against ASC compared to control cells (Jurkat/neo) (Figure 2c ), suggesting that ASC induces a mitochondria-dependent pathway of apoptosis.
ASC requires the activation of the initiator caspase-2
Although mitochondria seemed to be required for ASCmediated apoptosis, additional organelles may contribute to cellular stress sensing (Bratton and Cohen, 2001) , and thus, initiator caspases other than caspase-9 may be involved. We therefore compared the kinetic by which the initiator caspase-2, -9, and -8 and the effector caspase-3 are activated by ASC. The activation of caspase-8 correlated well with the activation of the effector caspase-3 corroborating the finding that ASCtriggered apoptosis occurs independent of death receptors. Interestingly, caspase-2 processing seemed to be more pronounced at 4 h than that of caspase-9 ( Figure 3a) .
Consequently, we asked whether the activation of caspase-2 is required for ASC-induced apoptosis. In fact, pretreatment of Jurkat T cells with the specific caspase-2 inhibitor zVDVADfmk (25 mM, 1 h) almost completely abrogated ASC-mediated apoptosis ( Figure 3b ).
Altogether, these data suggest an initial and relevant role for caspase-2 in ASC-triggered apoptosis.
ASC-triggered caspase-2 activation precedes mitochondrial dysfunction and caspase-9 activation
In order to clarify whether caspase-2 indeed precedes mitochondrial caspase-9 activation, we incubated Jurkat/bcl-x L cells with ASC (5 mM) and examined caspase-2 processing. In fact, we found caspase-2 processed in Jurkat/bcl-x L cells, indicating that caspase-2 activation occurs upstream of mitochondrial events. As control, we also examined the processing of caspase-8 in Jurkat/bcl- Figure 4a ). Etoposide (25 mg/ml) was used as a positive control (Robertson et al., 2000) .
If caspase-2 acts upstream of caspase-9, the caspase-2 inhibitor zVDVADfmk should prevent caspase-9 activation. In fact, cleavage of procaspase-9 was strongly reduced after pretreatment with the caspase-2 inhibitor zVDVADfmk (Figure 4b ).
To further strengthen our finding, we performed caspase activity assays for caspase-2 and -9. Figure 4c shows that after 3 h of ASC-treatment, caspase-2 activity is significantly increased whereas caspase-9 is still inactive. These data are in line with the results obtained by Western blot analysis (Figure 3a) .
How then is caspase-2 activation linked to mitochondrial dysfunction? A conceivable possibility would be the cleavage of Bid. Truncated Bid (tBid) translocates to the mitochondria and induces cytochrome c release (Luo et al., 1998) . We therefore investigated whether ASC induces Bid cleavage and whether this cleavage is inhibited by the specific caspase-2 inhibitor zVDVADfmk. Figure 4d shows increased protein levels of tBid in response to ASC (5 mM) treatment. This increased tBid levels were reduced to control levels by zVDVADfmk (25 mM, 1 h pretreatment).
Together, these results suggest that caspase-2 activation lies upstream of ASC-induced mitochondrial 'activation' and that Bid cleavage by caspase-2 may contribute to mitochondrial perturbation.
ASC activates JNK, which contributes to caspase-2 and -9 activation ASC may act by oxidatively damaging DNA (Matsumoto et al.,. 2003) . Indeed, FACS analysis revealed a time-dependent intracellular ROS production in response to ASC (5 mM). Staurosporine (0.5 mM) was used as a positive control (Cai and Jones, 1998) (Figure 5a ). We therefore hypothesized that ASC might activate c-Jun N-terminal protein kinase (JNK), which might be involved in ASC-induced apoptosis signaling. Timecourse studies revealed that ASC activates/phosphorylates JNK after 4 h (Figure 5b ) paralleling caspase-2 activation. The activation of JNK occurred upstream of mitochondria as overexpression of Bcl-x L was unable to abrogate JNK phosphorylation (Figure 5c ). ASCtriggered ROS generation contributed significantly to JNK activation since the antioxidant N-acetylcysteine (NAC) almost completely abrogated JNK phosphorylation (Figure 5d ). Employing the specific JNK inhibitor SP600125 10 mM (Bennett et al., 2001) , we found that caspase-2 and -9 processing was reduced (Figure 5e ), suggesting that JNK acts upstream of both, caspase-2 and -9. In agreement with this, cytochrome c release from mitochondria was also diminished after pretreatment with SP600125 (10 mM, 15 min) (Figure 5f ). SP600125 also lowered ASC-induced DNA fragmentation significantly (Figure 5g) .
What might be the JNK target linking JNK activation to mitochondrial cell death? Transcription factors that mediate the expression of certain proteins can be excluded since protein synthesis was not required for apoptosis induced by ASC (data not shown). The antiapoptotic proteins Bcl-2 and Bcl-x L are attractive targets that were shown to be phosphorylated by JNK and thus inactivated (Yamamoto et al., 1999; Kharbanda et al., 2000) . However, we were unable to detect Bcl-2 family phosphorylation, as determined by migration shift on SDS-PAGE (data not shown).
Together, these data give evidence that ASC triggers JNK activation via ROS generation. Active JNK then contributes via a nonidentified target to caspase activation and cytochrome c release. 8 h ), or pretreated with either zVADfmk (25 mM, 1 h) or zVDVADfmk (25 mM, 1 h) and then incubated with ASC (5 mM). Apoptosis was measured as described under Materials and methods by counting nuclei with a subdiploid DNA content. Bars, the mean7s.e. of three independent experiments performed in duplicate; **Po0.01, ***Po0.001 (Student's t test)
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Discussion
The present study reveals that ASC triggers apoptosis by a mechanism that utilizes the initiator caspase-2 and JNK to induce mitochondrial dysfunction and subsequent apoptosis. This view is supported by the following observations: (a) the CD95 death receptor is not required for ASC-induced apoptosis as the neutralizing antibody ZB4 was unable to prevent apoptosis; (b) in contrast, mitochondrial dysfunction, including cytochrome c release and dissipation of Dc m , was necessary for cell death since Jurkat/bcl-2 and Jurkat/bcl-x L were protected against ASC; (c) kinetic and inhibitor studies revealed that caspase-2 was not only the first initiator caspase processed in response to ASC but was also required for DNA fragmentation; (d) ASC-induced and zVDVADfmk-inhibitable Bid cleavage indicated a possible link between caspase-2 and mitochondria via Bid; (e) JNK was shown to be phosphorylated upstream of caspase-2 and mitochondria in response to ASC most likely via ROS induction. The picture that emerges from the presented data suggests that ASC induces ROS that activate JNK, which is followed and possibly paralleled by the processing of caspase-2 and subsequent mitochondrial dysfunction and apoptosis.
The most interesting and important finding of the present study is that caspase-2 is activated upstream of mitochondria and that this activation is necessary for ASC-induced apoptosis. This finding together with very recent reports may shed new light on this little attended initiator caspase (Guo et al., 2002; Paroni et al., 2002; Read et al., 2002; Robertson et al., 2002) . Although caspase-2 is classified as an initiator caspase and several stimuli, including CD95-L, growth factor withdrawal and DNA damaging agents, were shown to activate caspase-2 (Harvey et al., 1997; Stefanis et al., 1998; Droin et al., 2001; Robertson et al., 2002) , some studies fueled doubt as to whether caspase-2 plays a significant role as initiator caspase by showing that the effector caspase-3 is required for the activation of caspase-2, and caspase-2 is unable to cleave caspase-3 (Harvey et al., 1996; Stefanis et al., 1998; Slee et al., 1999) . Moreover, very recent experiments with caspase-2-deficient mice showed that although caspase-2 is activated in response to a broad range of stimuli, it is not essential for apoptosis in many cell types (O'Reilly et al., 2002) . The same group provided evidence that cell stress-induced activation of caspase-2 is dependent on the presence of Apaf-1 and caspase-9 (O'Reilly et al. proposed caspase-2 activation in an Apaf-1-independent putative caspase-2 activation complex. Procaspase-2 was also suggested to be recruited to the CARD domain of CRADD, an adaptor molecule for the TNF receptor, allowing the autocatalytic activation of caspase-2 (Duan and Dixit, 2002) . Subsequent events, however, remained largely unknown. A very recent report provided evidence that active caspase-2 can activate mitochondria either directly or via Bid cleavage suggesting that caspase-2 is a direct effector of the mitochondrial apoptotic pathway (Guo et al., 2002) . Furthermore, caspase-2 was demonstrated to be a nuclear resident protein that is able to trigger mitochondrial dysfunction from the nucleus (Paroni et al., 2002) . This view is supported by very recent findings that show that the cell cycle regulatory nuclear protein cyclin D3 interacts with and activates caspase-2 (Mendelsohn et al., 2002) . Thus, it might be conceivable that drugs affecting the nucleus may lead to the activation of caspase-2 and subsequent mitochondrial apoptotic cell death. This is also supported by the observation that the adaptor molecule CRADD is localized to some extent in the nucleus (ShearwinWhyatt et al., 2000) . An essential role for the initiator caspase-2 acting from the nucleus was discussed recently for etoposide-induced apoptosis when applied at low concentrations (10 mM) (Robertson et al., 2000 (Robertson et al., , 2002 . In fact, using etoposide as a positive control, we found that both compounds, ASC and etoposide, seem to utilize quite similar signaling pathways. A very recent study by Lassus et al. (2002) led to the concept that the initiator caspase-2 plays a similar role in stressinduced apoptosis as caspase-8 in cytokine-induced apoptosis. In both pathways, mitochondria are amplifiers of caspase activity rather than initiators of caspase activation. The present study supports this novel view of apoptotic signaling. Representative Western blots show reduced cleavage of caspase-2 and -9, respectively, after preincubation with the JNK inhibitor SP600125. Jurkat T cells were left untreated (Control), treated with ASC (5 mM, 4 h), or pretreated with SP600125 (10 mM, 15 min) and then incubated with ASC (5 mM). (f) Cytochrome c release depends on JNK activity. Representative Western blot demonstrating reduced cytochrome c release after preincubation with SP600125. Cells were left untreated (Control), treated with ASC (5 mM, 6 h), or pretreated with SP600125 (10 mM, 15 min) and then incubated with ASC (5 mM). (g) Reduction of ASC-induced apoptosis by SP600125. Cells were left untreated (Control), treated with ASC (5 mM, 8 h), or pretreated with SP600125 (10 mM, 15 min) and then incubated with ASC (5 mM). Apoptotic cells were quantified as described under Materials and methods. Bars, the mean7s.e. of three independent experiments performed in duplicate; *Po0.05 (Student's t test) Persistent activation of JNK is frequently associated with cell death and many studies suggest a role of JNK as a positive mediator in stress-induced apoptosis (Barr and Bogoyevitch, 2001) . JNK was found to be phosphorylated upstream of mitochondria in response to ASC and to require ROS since the antioxidant NAC completely abrogated JNK phosphorylation. Use of the specific JNK inhibitor SP600125 partially reduced caspase-2 and -9 activation as well as cytochrome c release, suggesting that JNK indeed contributes to ASCinduced mitochondrial dysfunction. Inhibition of JNK also led to a significant but moderate reduction of ASC-mediated DNA fragmentation. Altogether, active JNK seems to be a contributor rather than the sole required factor for ASC-triggered cell death. The requirement of JNK in stress-induced cell death appears to be highly dependent on the cell type and the signaling context: transient activation of JNK when also accompanied by survival pathways, including Akt kinase and ERK1/2 MAPK, may not be associated with cell death (Barr and Bogoyevitch, 2001; Antlsperger et al., 2003) . ASC-induced JNK activation occurs transiently: phospho-JNK was visible at 4 and 8 h only (Figure 5a ). In addition, we also observed an activation of Akt kinase, but no activation of ERK1/2 (unpublished data). This specific signaling context and the transient activation of JNK may explain why JNK contributes but is not required for ASC-induced cell death. Few targets are identified that are suggested to mediate the proapoptotic activity of JNK. Those are mainly transcription factors, such as AP-1, ATF-2 and Elk-1 and the antiapoptotic Bcl-2 family members Bcl-2 and Bcl-x L (Barr and Bogoyevitch, 2001; Herr and Debatin, 2001 ). None of these targets, however, can seriously be considered as targets of ASC-activated JNK since neither inhibition of protein synthesis affected apoptosis excluding transcription factors as potential targets, nor did we find any indication of Bcl-2 or Bcl-x L phosphorylation (unpublished results). Thus, as stated earlier, the exact target of JNK in the release of cytochrome c is yet to be established (Barr and Bogoyevitch, 2001) .
In summary, we provided evidence that the marine pyridoacridine alkaloid ASC triggers apoptotic cell death in leukemia Jurkat T cells by a signaling cascade that requires the activation of the initiator caspase-2 upstream of mitochondria. Redox-sensitive activation of JNK was shown to contribute to the activation of caspase-2 and mitochondrial dysfunction.
Materials and methods
Cells and culture conditions
Human leukemia Jurkat T cells (clone J16) as well as Jurkat cells transfected with vector control, Bcl-x L or Bcl-2 (Walczak et al., 2000) (kindly provided by Drs PH Krammer and H Walczak, Heidelberg, Germany and Dr K Schulze-Osthoff, Mu¨nster, Germany) were cultivated as described (Dirsch et al., 2001) . The medium of transfected cells was supplemented with 1 mg/ml G418 (Life Technologies) in every fifth passage.
Compounds
Synthesized ASC (pyrido[2,3,4-kl]-acridine) (Bracher, 1993) was dissolved in DMSO (10 mM stock) and stored at À201C. The final DMSO concentration in cell culture supernatants did not exceed 1%, a concentration verified not to interfere with the experiments performed. Etoposide was purchased from Calbiochem; the soluble CD95L was from Alexis Biochemicals. Propidium iodide was obtained from Sigma.
Antibodies and inhibitors
Caspase-2 (G310-1248), caspase-3 (clone 19), cytochrome c (7H8.2C12) were all from Becton Dickinson; caspase-8 (5F7) was from Upstate Biotechnology; caspase-9 (clone 1-2) and the inhibitors zVADfmk, zVDVADfmk, SP600125 were purchased from Calbiochem, Bid (polyclonal) was a kind gift from Dr X Wang (University of Texas Southwestern Medical Center Dallas, USA); Bcl-x L and Bcl-2 (polyclonal) were from Santa Cruz; phospho-JNK (Thr 
Cell viability
Impaired cell viability was measured using the MTT assay as described previously (Dirsch et al., 2001 ).
Quantification of apoptosis
The rate of apoptotic cell death was quantified by determining DNA fragmentation according to Nicoletti et al. (1991) . Briefly, cells were incubated for 24 h in a hypotonic buffer (1% sodium citrate, 0.1% Triton X-100, 50 mg/ml propidium iodide) and analysed by flow cytometry on a FACScalibur (Becton Dickinson) using CellQuest software. Nuclei to the left of the 'G1-peak' containing hypodiploid DNA were considered apoptotic.
Western blot analysis
Cells were harvested, washed with ice-cold PBS, and lysed in 1% Triton X-100, 0.15 M NaCl, and 10 mM Tris-HCl (pH 7.4), supplemented with the protease inhibitor completet (Roche, Germany) or, in case of phospho-protein detection, in 50 mM HEPES, 50 mM NaCl, 5 mM EDTA, 10 mM tetrasodium pyrophosphate, 50 mM NaF, 1 mM sodium orthovanadate, 1 mM PMSF, 1% Triton X-100, supplemented with completet (Roche) for 30 min at 81C. Lysates were centrifuged at 10 000 g for 10 min at 41C. Protein concentration was determined by the Bradford method. Equal amounts of protein were separated by SDS-PAGE (10% for caspase-8, 12% for caspase-2, -3, -9, phospho-JNK, and Bcl-2 proteins, 15% for cytochrome c), transferred onto polyvinylidene difluoride membranes (Immobilon-P; Millipore). Equal protein loading was controlled by Coomassie Blue staining of gels. Membranes were blocked with 5% nonfat dry milk in Tris-buffered saline (50 mM Tris pH 8.0, 150 mM NaCl) with 0.2% Tween 20 (TBS-T pH 8.0) for 1 h and then incubated with specific antibodies overnight at 41C. Specific proteins were visualized by secondary antibodies conjugated to horseradish peroxidase and the Renaissance s Plus reagent (Perkin-Elmer). Pictures were taken on a Kodak Digital Sciencet Image station 440CF (Perkin-Elmer).
Measurement of cytochrome c release
The release of cytochrome c from mitochondria was analysed according to Leist et al. (1998) . Briefly, cell pellets were resuspended in permeabilization buffer (210 mM D-mannitol, 70 mM sucrose, 10 mM HEPES, 5 mM succinate, 0.2 mM EGTA, 0.15% BSA, and 80 mg/ml digitonin, pH 7.2) and incubated for 20 min at 41C. Permeabilized cells were centrifuged (170 g, 10 min, 41C). The supernatant was removed and centrifuged again (13 000 g, 10 min, 41C). The obtained cytosol was probed for cytochrome c as described above. The remaining pellet of permeabilized cells was lysed in 0.1% Triton/PBS (15 min, 41C), centrifuged (13 000 g, 10 min, 41C) and the supernatant containing mitochondrial cytochrome c analysed by SDS-PAGE.
Measurement of ROS generation
The production of ROS by Jurkat T cells was measured by flow cytometry basically as described previously (Dirsch et al.,. 1998 ) employing 200 mM carboxy-H 2 DCFDA (Molecular Probes).
Analysis of the mitochondrial transmembrane potential (Dc m )
Cells were stained with the fluorochrome JC-1 (1.25 mg/ml; Molecular Probes) and Dc m was measured as described (Dirsch et al., 2001 ).
Analysis of caspase activity
Cells (1 Â 10 6 ) were collected by centrifugation, washed with ice-cold PBS and frozen at À201C overnight. The activity assay was performed according to the manufacturer's instructions of the fluorometric caspase-2 (VDVAD-AFC) and caspase-9 (LEHD-AFC) assay kit (Calbiochem). The generation of free AFC at 371C was determined by fluorescence measurement (Fluostar; SLT Labinstruments) set at an excitation wavelength of 390 nm and an emission wavelength of 505 nm.
